JP2021536237A5 - - Google Patents
Info
- Publication number
- JP2021536237A5 JP2021536237A5 JP2021510710A JP2021510710A JP2021536237A5 JP 2021536237 A5 JP2021536237 A5 JP 2021536237A5 JP 2021510710 A JP2021510710 A JP 2021510710A JP 2021510710 A JP2021510710 A JP 2021510710A JP 2021536237 A5 JP2021536237 A5 JP 2021536237A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- car
- motif
- treg
- binding
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024111754A JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1814203.4A GB201814203D0 (en) | 2018-08-31 | 2018-08-31 | Engineered regulatory t cell |
| GB1814203.4 | 2018-08-31 | ||
| PCT/GB2019/052422 WO2020044055A1 (en) | 2018-08-31 | 2019-08-30 | Engineered regulatory t cell |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111754A Division JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021536237A JP2021536237A (ja) | 2021-12-27 |
| JPWO2020044055A5 JPWO2020044055A5 (https=) | 2022-09-05 |
| JP2021536237A5 true JP2021536237A5 (https=) | 2022-09-05 |
Family
ID=63920789
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021510710A Pending JP2021536237A (ja) | 2018-08-31 | 2019-08-30 | 改変された制御性ｔ細胞 |
| JP2024111754A Pending JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024111754A Pending JP2024138456A (ja) | 2018-08-31 | 2024-07-11 | 改変された制御性ｔ細胞 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210338726A1 (https=) |
| EP (1) | EP3844264A1 (https=) |
| JP (2) | JP2021536237A (https=) |
| KR (1) | KR20210054543A (https=) |
| CN (1) | CN112969784A (https=) |
| AU (1) | AU2019333012A1 (https=) |
| CA (1) | CA3110012A1 (https=) |
| GB (2) | GB201814203D0 (https=) |
| IL (1) | IL280942A (https=) |
| SG (1) | SG11202101668TA (https=) |
| WO (1) | WO2020044055A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3714944A1 (en) * | 2019-03-29 | 2020-09-30 | Medizinische Hochschule Hannover | Car for use in the treatment of hvg disease |
| WO2019169290A1 (en) | 2018-03-02 | 2019-09-06 | Allogene Therapeutics, Inc. | Inducible chimeric cytokine receptors |
| AU2019254824B2 (en) | 2018-04-18 | 2025-04-24 | Ucl Business Ltd | Method for enhancing the suppressive properties of Treg cells |
| BR112021017365A2 (pt) | 2019-03-01 | 2022-02-01 | Allogene Therapeutics Inc | Receptores de citocina quiméricos constitutivamente ativos |
| EP3931208A1 (en) | 2019-03-01 | 2022-01-05 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors bearing a pd-1 ectodomain |
| WO2021041806A1 (en) | 2019-08-30 | 2021-03-04 | Allogene Therapeutics, Inc. | Chimeric cytokine receptors comprising tgf beta binding domains |
| JP2023514407A (ja) | 2020-02-24 | 2023-04-05 | アロジーン セラピューティクス，インコーポレイテッド | 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞 |
| CN115427440A (zh) * | 2020-02-25 | 2022-12-02 | 圭尔医疗有限公司 | 用于工程化细胞的嵌合受体 |
| JP2023521519A (ja) * | 2020-04-06 | 2023-05-24 | セレディット エルエルシー | キメラ抗原受容体を発現し低減した炎症性サイトカインシグナル伝達を有する遺伝子改変された免疫細胞 |
| CN112852748B (zh) * | 2020-04-16 | 2023-11-21 | 成都仕康美生物科技有限公司 | 靶向HLA-A的嵌合抗原受体、编码基因、CAR-Tregs细胞及其制备方法、用途 |
| GB202007842D0 (en) | 2020-05-26 | 2020-07-08 | Quell Therapeutics Ltd | Polypeptide useful in adoptive cell therapy |
| CN115768870A (zh) * | 2020-06-01 | 2023-03-07 | 促进军事医学的亨利·M·杰克逊基金会公司 | 诱导型调节性t细胞，其生产方法及其用途 |
| AU2021289144A1 (en) | 2020-06-11 | 2022-12-15 | King's College London | TREM2 chimeric receptor |
| CN111849916B (zh) * | 2020-07-21 | 2021-08-27 | 广东先康达生物科技有限公司 | 一种免疫细胞及其制剂与应用 |
| GB202013477D0 (en) | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| GB202017678D0 (en) | 2020-11-09 | 2020-12-23 | Quell Therapeutics Ltd | Method for cryopreserving engineered tregs |
| EP4240376B1 (en) | 2020-11-09 | 2026-03-25 | Quell Therapeutics Limited | Method for cryopreserving engineered tregs |
| US20240052015A1 (en) | 2020-12-23 | 2024-02-15 | Quell Therapeutics Limited | Inducible signalling protein |
| JP2024524865A (ja) * | 2021-06-08 | 2024-07-09 | ザ メソディスト ホスピタル | 制御性Ｔ細胞（Ｔｒｅｇ）集団を製造するための方法、Ｔｒｅｇ組成物、及び治療のための方法 |
| GB202108366D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Multichain chimeric antigen receptor |
| GB202108364D0 (en) | 2021-06-11 | 2021-07-28 | Quell Therapeutics Ltd | Chimeric receptor |
| WO2023047100A1 (en) | 2021-09-21 | 2023-03-30 | Quell Therapeutics Ltd | Anti-trem2 chimeric antigen receptor |
| TW202321286A (zh) | 2021-09-21 | 2023-06-01 | 英商圭爾醫療有限公司 | 抗p75ntr嵌合抗原受體 |
| GB202117298D0 (en) | 2021-11-30 | 2022-01-12 | Quell Therapeutics Ltd | Signalling protein |
| WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
| US20250017967A1 (en) | 2021-12-17 | 2025-01-16 | Quell Therapeutics Limited | Anti-thymocyte globulin for immunomodulation of a subject with regulatory t cells |
| CN118434761A (zh) | 2021-12-22 | 2024-08-02 | 圭尔医疗有限公司 | 组成型细胞因子受体 |
| US20250099584A1 (en) * | 2022-02-18 | 2025-03-27 | Institut National de la Santé et de la Recherche Médicale | Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance |
| WO2023180690A1 (en) | 2022-03-22 | 2023-09-28 | Quell Therapeutics Limited | Methods and products for culturing t cells and uses thereof |
| JP2025527729A (ja) * | 2022-08-26 | 2025-08-22 | ソノマ バイオセラピューティクス， インコーポレイテッド | テザリングされたインターロイキン２組み換え受容体及び使用方法 |
| GB202217541D0 (en) | 2022-11-24 | 2023-01-11 | Quell Therapeutics Ltd | Recombinant receptor |
| WO2024133472A1 (en) | 2022-12-22 | 2024-06-27 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| KR20250169635A (ko) | 2023-01-23 | 2025-12-03 | 메디치니쉐 호흐슐레 하노버 | 항-entpd3 키메라 항원 수용체 |
| IL322333A (en) | 2023-02-07 | 2025-09-01 | Quell Therapeutics Ltd | Culture method for TREG cells |
| EP4669343A1 (en) | 2023-02-24 | 2025-12-31 | Medizinische Hochschule Hannover | CHIMERIC ANTIGEN RECIPIENT |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4680728A1 (en) | 2023-03-17 | 2026-01-21 | Quell Therapeutics Limited | Treg therapy |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| CN121586582A (zh) | 2023-03-20 | 2026-02-27 | 汉诺威医学院 | 嵌合抗原受体 |
| WO2024194642A1 (en) | 2023-03-22 | 2024-09-26 | Quell Therapeutics Limited | Engineered t regulatory cell |
| WO2024254450A1 (en) * | 2023-06-07 | 2024-12-12 | Cellmidi Company Limited | Improved endodomains and immune cells comprising the same |
| EP4731648A1 (en) | 2023-06-21 | 2026-04-29 | Quell Therapeutics Limited | Constitutive cytokine receptors |
| WO2026008994A1 (en) | 2024-07-04 | 2026-01-08 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| WO2014153114A1 (en) * | 2013-03-14 | 2014-09-25 | Fred Hutchinson Cancer Research Center | Compositions and methods to modify cells for therapeutic objectives |
| ES2857998T3 (es) * | 2015-02-12 | 2021-09-29 | Univ Health Network | Receptores de antígenos quiméricos |
| GB201518816D0 (en) * | 2015-10-23 | 2015-12-09 | Autolus Ltd | Receptor |
| US20180320133A1 (en) * | 2015-11-05 | 2018-11-08 | City Of Hope | Methods for preparing cells for adoptive t cell therapy |
| WO2017100428A1 (en) * | 2015-12-09 | 2017-06-15 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
| WO2017172981A2 (en) * | 2016-03-29 | 2017-10-05 | University Of Southern California | Chimeric antigen receptors targeting cancer |
| CN109415698A (zh) * | 2016-06-16 | 2019-03-01 | 斯隆－凯特林纪念癌症中心 | 工程化Treg细胞 |
| CA3034691A1 (en) * | 2016-08-30 | 2018-03-08 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use for treating viral and other infections |
| EP3580212A4 (en) * | 2017-02-08 | 2021-03-17 | Dana Farber Cancer Institute, Inc. | REGULATION OF CHEMERIC ANTIGEN RECEPTORS |
| JP7618192B2 (ja) * | 2017-03-28 | 2025-01-21 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 移植された組織を拒絶反応から保護するための方法 |
-
2018
- 2018-08-31 GB GBGB1814203.4A patent/GB201814203D0/en not_active Ceased
-
2019
- 2019-08-30 WO PCT/GB2019/052422 patent/WO2020044055A1/en not_active Ceased
- 2019-08-30 JP JP2021510710A patent/JP2021536237A/ja active Pending
- 2019-08-30 AU AU2019333012A patent/AU2019333012A1/en not_active Abandoned
- 2019-08-30 KR KR1020217009384A patent/KR20210054543A/ko active Pending
- 2019-08-30 SG SG11202101668TA patent/SG11202101668TA/en unknown
- 2019-08-30 GB GB2104653.7A patent/GB2591929B/en active Active
- 2019-08-30 US US17/272,126 patent/US20210338726A1/en active Pending
- 2019-08-30 CA CA3110012A patent/CA3110012A1/en active Pending
- 2019-08-30 CN CN201980067986.5A patent/CN112969784A/zh active Pending
- 2019-08-30 EP EP19763058.5A patent/EP3844264A1/en active Pending
-
2021
- 2021-02-17 IL IL280942A patent/IL280942A/en unknown
-
2024
- 2024-07-11 JP JP2024111754A patent/JP2024138456A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021536237A5 (https=) | ||
| JPWO2020044055A5 (https=) | ||
| GB2591929A (en) | Engineered regulatory T Cell | |
| Leung | Use of NK cell activity in cure by transplant | |
| Fierabracci et al. | Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles | |
| Castro-Manrreza et al. | Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications | |
| US20250283040A1 (en) | Methods to Expand a T Regulatory Cell Master Cell Bank | |
| JP2022185024A (ja) | Ｔ細胞前駆体を産生させるための方法 | |
| GB2609103A (en) | Chimeric receptors for use in engineered cells | |
| EP4545639A2 (en) | Engineered gamma delta t-cells | |
| JP2008508885A5 (https=) | ||
| JP2019536461A5 (https=) | ||
| WO2017015490A1 (en) | T cells for expression of chimeric antigen receptors and other receptors | |
| JP2021511041A5 (https=) | ||
| EP3882337A1 (en) | Compositions and methods for diminishing an immune response | |
| CN102876630A (zh) | 一种高效分离和扩增人脐带血间充质干细胞的方法 | |
| ZA200601074B (en) | Autologous self-tolerance inducing cells of monocytic origin and their use in pharmaceutical preparations | |
| US10758573B2 (en) | Compositions and methods for enrichment of cells | |
| JP2012527237A (ja) | 免疫介在性疾患における臨床応用のための、抑制機能の高められた制御性ｔ細胞のエクスビボ増加方法 | |
| JP2016539635A (ja) | 抗原特異的調節性ｔ細胞の誘導方法 | |
| Ulusoy et al. | Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice | |
| Moirangthem et al. | A DL-4-and TNFα-based culture system to generate high numbers of nonmodified or genetically modified immunotherapeutic human T-lymphoid progenitors | |
| US20170106021A1 (en) | Compositions enriched for hox11+ stem cells and methods of preparing the same | |
| EP4289859A1 (en) | Fusion protein for maintenance of regulatory t-cells | |
| JP2007521803A (ja) | レギュレーター／サプレッサーｔリンパ球の同定および調製のための方法、その組成物、並びにその使用 |